Diffuse large B-cell lymphoma (DLBCL), is an aggressive disease affecting B-lymphocytes. Despite being aggressive, DLBCL is considered curable. There are many novel therapies and combination regimens currently being studied in clinical trials for the treatment of both newly diagnosed and relapsed/refractory DLBCL. Recently approved treatments, as well as those on the horizon, provide new hope for patients as therapeutic options become more targeted to and personalized for their disease.
With these recent advancements, community cancer programs need to be educated on the role these therapies will play in the community setting and how best to integrate these new treatments into practice. In response, ACCC has developed an educational initiative called Reframing the Conversation: Effective Practices for Diffuse Large B-cell Lymphoma. The aim of this project is to reframe the conversation between patients and providers to incorporate new therapy advancements, set expectations with patients about their treatment journey, and give them more confidence that there is new hope.
This will be accomplished by:
For more information on this project, please contact the ACCC Provider Education department.
The following institutes are reframing the conversation between DLBCL patients and providers by incorporating new therapy advancements and setting realistic expectations, highlighting the supportive care strategies.
A collection of curated resources designed to enhance and support diffuse large B-cell lymphoma (DLBCL) cancer care.
This effective practice guide reviews the treatment landscape for patients with DLBCL and includes a patient-provider communication roadmap and strategies to foster patient-centric discussions through shared decision-making.
